Search

Search Results

1. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)

   The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in...

   A. González del Alba, M. J. Méndez-Vidal, ... J. A. Arranz in Clinical and Translational Oncology

   Article Open access 24 February 2021

2. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer

   Background

   The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer...

   Takeo Kosaka, Hiroshi Hongo, ... Mototsugu Oya in Cancer Chemotherapy and Pharmacology

   Article Open access 03 October 2018
   

3. Multiple drugs

   in Reactions Weekly

   Article 26 November 2022

4. Abiraterone/denosumab/radium-223-chloride

   in Reactions Weekly

   Article 04 May 2024

5. Prostatic Artery Embolization in Patients with Advanced Prostate Cancer: A Prospective Single Center Pilot Study

   Purpose

   To assess efficacy and safety of prostatic artery embolization (PAE) in patients with advanced prostate cancer (PCa).

   Materials and Methods ...

   Orlando Burkhardt, Dominik Abt, ... Gautier Müllhaupt in CardioVascular and Interventional Radiology

   Article 28 February 2024
   

6. Multiple drugs

   in Reactions Weekly

   Article 22 April 2023

7. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer

   Purpose

   In some patients with prostate cancer, bone marrow carcinomatosis develops later in the course of the disease, which has a poor prognosis....

   Tobias Peres, Stefanie Aeppli, ... Christian Rothermundt in Journal of Cancer Research and Clinical Oncology

   Article Open access 08 February 2024
   

8. Estrogen

   in Reactions Weekly

   Article 25 November 2023

9. Multiple drugs

   in Reactions Weekly

   Article 01 April 2023

10. Multiple drugs

    in Reactions Weekly

    Article 01 July 2023

11. Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management

    The management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding...

    Tivya Kulasegaran, Niara Oliveira in Current Treatment Options in Oncology

    Article Open access 24 June 2024

12. Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

    Background and aims

    [ ¹⁷⁷ Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a new therapy for patients with metastatic castration-resistant prostate...

    Sazan Rasul, Markus Hartenbach, ... Alexander R. Haug in European Journal of Nuclear Medicine and Molecular Imaging

    Article Open access 30 October 2020
    

13. Role of volumetric parameters obtained from ⁶⁸ Ga-PSMA PET/CT and ¹⁸F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy

    Objective

    The aim of this study was to determine the prognostic role of volumetric parameters and Pro-PET scores obtained from ⁶⁸ Ga-prostate-specific...

    Yunus Güzel, Halil Kömek, ... Cihan Gündoğan in Annals of Nuclear Medicine

    Article 18 June 2023
    

14. Antineoplastics/corticosteroids

    in Reactions Weekly

    Article 12 November 2022

15. A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), October 15th – 19th, 2022, Barcelona

    in memo - Magazine of European Medical Oncology

    Article 26 April 2023

16. Therapie des metastasierten kastrationsresistenten Prostatakarzinoms

    Background

    For many decades metastatic, castration-resistant prostate cancer (mCRPC) was thought to be treatment inaccessible. However, today, five...

    G. von Amsberg, A. S. Merseburger in Der Urologe

    Article 09 April 2020

17. Small-Cell Carcinoma of the Prostate – Challenges of Diagnosis and Treatment: A Next of Kin and Physician Perspective Piece

    This article was co-authored by a patient’s relative describing their experiences of receiving a diagnosis and subsequent clinical management of a...

    Trish Abbott, Kenrick Ng, ... Paula Muehlschlegel in Oncology and Therapy

    Article Open access 25 June 2023
    

18. Systemtherapie des Prostatakarzinoms im hohen Alter

    Background

    The vast majority of prostate cancer (PCa) patients are diagnosed beyond the age of 65. However, older, frail patients are often...

    Gunhild v. Amsberg, Tobias Busenbender, ... Carsten Bokemeyer in Die Onkologie

    Article 26 January 2024

19. Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

    Objectives

    The aim of this study was to perform a budget impact analysis (BIA) of introducing olaparib treatment for adult patients with metastatic...

    Natalia Espinola, Constanza Silvestrini, ... Federico Augustovski in PharmacoEconomics - Open

    Article Open access 13 July 2024
    

20. Use of PSMA PET/CT to detect prostate cancer metastatic to a preexisting thyroid nodule

    Prostate cancer (PCa) seldom metastasizes to the thyroid gland, and only a limited number of cases are documented in the literature. The application...

    Cameron Chalker, Burçak Yilmaz, ... Alexandra O. Sokolova in npj Precision Oncology

    Article Open access 15 June 2024